SCHEMBL5730857

SCHEMBL5730857

CC(C)(C)c1cccc([C]2CCC(C#N)CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.41
CTSS P25774 2/20 0.39
CTSK P43235 1/20 0.39
RXRA P19793 2/20 0.38
RXRB P28702 2/20 0.38
PIM1 P11309 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
PTAFR P25105 1/20 0.32
NAAA Q02083 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5730248 0.80 KIF11 (0.45) KIF11CTSSCTSKRXRARXRB
SCHEMBL5729516 0.76 KIF11 (0.41) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL2874345 0.75 KIF11 (0.50) KIF11CTSSCTSKRXRARXRB
SCHEMBL4264351 0.75 KIF11 (0.41) KIF11CTSSCTSKRXRARXRB
SCHEMBL5730863 0.74 HTR2C (0.42) CTSSCTSKALDH1A1KDM4EHDAC4
SCHEMBL5729488 0.74 KIF11 (0.40) KIF11RXRARXRBHDAC4HDAC2
SCHEMBL5729463 0.72 KIF11 (0.47) KIF11CTSSCTSKRXRARXRB
SCHEMBL4260083 0.72 KIF11 (0.51) KIF11CTSSCTSKRXRARXRB
SCHEMBL5729388 0.71 KIF11 (0.46) KIF11CTSSCTSKRXRARXRB
SCHEMBL5729232 0.70 KIF11 (0.45) KIF11CTSSCTSKRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735293-A2 SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-12-27 EP disclosed
US-20050239790-A1 Substituted hydroxyethylamine aspartyl protease inhibitors ELAN PHARMACEUTICALS, INC. 2005-10-27 US disclosed
WO-2005087752-A2 SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239790-A1 Substituted hydroxyethylamine aspartyl protease inhibitors DNPEP, MME, ANPEP KIF11 4615/4885CTSS 222/4885CTSK 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.